← Back to Clinical Trials
Recruiting NCT06075628

NCT06075628 Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06075628
Status Recruiting
Phase
Sponsor Kansas City Heart Rhythm Research Foundation
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-07-24
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Left Atrial Appendage Occlusion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-07-24 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is intended to assess the incidence and correlation to the development of peri-device leaks (PDLs), device related thrombosis (DRTs) and cerebral vascular accident (CVA)/transient ischemic attacks (TIAs) in association with left atrial appendage contrast flow (LAA-CF). It will be a multi-center, retrospective study. Approximately 100 subject charts will be reviewed.

Eligibility Criteria

Inclusion Criteria: * Subjects must be at least 18 years of age. * Subjects underwent LAA closure with Watchman/Watchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022 Exclusion Criteria: * No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.

Contact & Investigator

Central Contact

Donita Atkins

✉ datkins@kchrf.com

📞 816-651-1969

Principal Investigator

Dhanunjaya Lakkireddy, MD

PRINCIPAL INVESTIGATOR

Kansas City Heart Rhythm Institute

Frequently Asked Questions

Who can join the NCT06075628 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06075628 currently recruiting?

Yes, NCT06075628 is actively recruiting participants. Contact the research team at datkins@kchrf.com for enrollment information.

Where is the NCT06075628 trial being conducted?

This trial is being conducted at Overland Park, United States.

Who is sponsoring the NCT06075628 clinical trial?

NCT06075628 is sponsored by Kansas City Heart Rhythm Research Foundation. The principal investigator is Dhanunjaya Lakkireddy, MD at Kansas City Heart Rhythm Institute. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology